Effect of autoimmune diseases on incidence and survival in subsequent multiple myeloma

<p>Abstract</p> <p>Background</p> <p>Patients with many types of autoimmune diseases (AIDs) are at an increased risk of cancer, which may depend on underlying dysregulation of the immune system or treatment. We systematically analyzed myeloma risk and survival in patien...

Full description

Bibliographic Details
Main Authors: Hemminki Kari, Liu Xiangdong, Försti Asta, Ji Jianguang, Sundquist Jan, Sundquist Kristina
Format: Article
Language:English
Published: BMC 2012-10-01
Series:Journal of Hematology & Oncology
Subjects:
Online Access:http://www.jhoonline.org/content/5/1/59
_version_ 1830283384298930176
author Hemminki Kari
Liu Xiangdong
Försti Asta
Ji Jianguang
Sundquist Jan
Sundquist Kristina
author_facet Hemminki Kari
Liu Xiangdong
Försti Asta
Ji Jianguang
Sundquist Jan
Sundquist Kristina
author_sort Hemminki Kari
collection DOAJ
description <p>Abstract</p> <p>Background</p> <p>Patients with many types of autoimmune diseases (AIDs) are at an increased risk of cancer, which may depend on underlying dysregulation of the immune system or treatment. We systematically analyzed myeloma risk and survival in patients diagnosed with 33 different AIDs.</p> <p>Methods</p> <p>Data on patients with AIDs were retrieved from the Swedish Hospital Discharge Register and were linked to myeloma diagnoses from the Cancer Registry. Standardized incidence ratios (SIR) and hazard ratios (HRs) were calculated for subsequent myeloma between 1964 and 2008.</p> <p>Results</p> <p>Among patients with the 33 AIDs analyzed, 457 cases of myeloma were diagnosed. The overall SIR for myeloma was 1.12 and the overall HR was 0.92 and non-significant. SIRs for myeloma were significantly increased after ankylosing spondylitis (2.02) and systemic sclerosis (2.63). Only the HR for myeloma after rheumatic fever (5.27) was significantly increased. The SIR for myeloma before age 60 years was 1.45; the SIR for myeloma was only increased in the period 1964–1990 (1.31) and not later (1.04). Only the SIR for myeloma after ankylosing spondylitis was increased in the period 1991–2008 (2.09); the HRs for myeloma were increased after polymyositis/dermatomyositis (6.44) and rheumatic fever (4.43) but there were only three deaths of myeloma after these AIDs.</p> <p>Conclusions</p> <p>The present data showed an increase in myeloma SIR after two AIDs, ankylosing spondylitis and systemic sclerosis, and in HR after rheumatic fever. The overall myeloma risk after any AID was no longer increased in the latter follow-up period of 1991 through 2008.</p>
first_indexed 2024-12-19T02:56:12Z
format Article
id doaj.art-ee4d28b64ff54954926dcb956174a3ab
institution Directory Open Access Journal
issn 1756-8722
language English
last_indexed 2024-12-19T02:56:12Z
publishDate 2012-10-01
publisher BMC
record_format Article
series Journal of Hematology & Oncology
spelling doaj.art-ee4d28b64ff54954926dcb956174a3ab2022-12-21T20:38:20ZengBMCJournal of Hematology & Oncology1756-87222012-10-01515910.1186/1756-8722-5-59Effect of autoimmune diseases on incidence and survival in subsequent multiple myelomaHemminki KariLiu XiangdongFörsti AstaJi JianguangSundquist JanSundquist Kristina<p>Abstract</p> <p>Background</p> <p>Patients with many types of autoimmune diseases (AIDs) are at an increased risk of cancer, which may depend on underlying dysregulation of the immune system or treatment. We systematically analyzed myeloma risk and survival in patients diagnosed with 33 different AIDs.</p> <p>Methods</p> <p>Data on patients with AIDs were retrieved from the Swedish Hospital Discharge Register and were linked to myeloma diagnoses from the Cancer Registry. Standardized incidence ratios (SIR) and hazard ratios (HRs) were calculated for subsequent myeloma between 1964 and 2008.</p> <p>Results</p> <p>Among patients with the 33 AIDs analyzed, 457 cases of myeloma were diagnosed. The overall SIR for myeloma was 1.12 and the overall HR was 0.92 and non-significant. SIRs for myeloma were significantly increased after ankylosing spondylitis (2.02) and systemic sclerosis (2.63). Only the HR for myeloma after rheumatic fever (5.27) was significantly increased. The SIR for myeloma before age 60 years was 1.45; the SIR for myeloma was only increased in the period 1964–1990 (1.31) and not later (1.04). Only the SIR for myeloma after ankylosing spondylitis was increased in the period 1991–2008 (2.09); the HRs for myeloma were increased after polymyositis/dermatomyositis (6.44) and rheumatic fever (4.43) but there were only three deaths of myeloma after these AIDs.</p> <p>Conclusions</p> <p>The present data showed an increase in myeloma SIR after two AIDs, ankylosing spondylitis and systemic sclerosis, and in HR after rheumatic fever. The overall myeloma risk after any AID was no longer increased in the latter follow-up period of 1991 through 2008.</p>http://www.jhoonline.org/content/5/1/59Autoimmune diseaseMultiple myelomaIncidenceSurvival
spellingShingle Hemminki Kari
Liu Xiangdong
Försti Asta
Ji Jianguang
Sundquist Jan
Sundquist Kristina
Effect of autoimmune diseases on incidence and survival in subsequent multiple myeloma
Journal of Hematology & Oncology
Autoimmune disease
Multiple myeloma
Incidence
Survival
title Effect of autoimmune diseases on incidence and survival in subsequent multiple myeloma
title_full Effect of autoimmune diseases on incidence and survival in subsequent multiple myeloma
title_fullStr Effect of autoimmune diseases on incidence and survival in subsequent multiple myeloma
title_full_unstemmed Effect of autoimmune diseases on incidence and survival in subsequent multiple myeloma
title_short Effect of autoimmune diseases on incidence and survival in subsequent multiple myeloma
title_sort effect of autoimmune diseases on incidence and survival in subsequent multiple myeloma
topic Autoimmune disease
Multiple myeloma
Incidence
Survival
url http://www.jhoonline.org/content/5/1/59
work_keys_str_mv AT hemminkikari effectofautoimmunediseasesonincidenceandsurvivalinsubsequentmultiplemyeloma
AT liuxiangdong effectofautoimmunediseasesonincidenceandsurvivalinsubsequentmultiplemyeloma
AT forstiasta effectofautoimmunediseasesonincidenceandsurvivalinsubsequentmultiplemyeloma
AT jijianguang effectofautoimmunediseasesonincidenceandsurvivalinsubsequentmultiplemyeloma
AT sundquistjan effectofautoimmunediseasesonincidenceandsurvivalinsubsequentmultiplemyeloma
AT sundquistkristina effectofautoimmunediseasesonincidenceandsurvivalinsubsequentmultiplemyeloma